Phlexglobal US Expansion Continues With Philadelphia Office Launch
Phlexglobal has announced its expansion across the United States with the opening of an office in Philadelphia, Pennsylvania.
Phlexglobal’s expansion across the US follows the success enjoyed by the organization’s California office which has seen exponential demand for its services across the North American territory.
The opening of the Philadelphia office comes hot on the heels of April’s management buy out (MBO) of the company by UK private equity firm Inflexion, which will allow Phlexglobal to further expand its provision of clinical trial support, underpinned by the recent launch of version 3 of the company’s eTMF solution, PhlexEview.
The new East Coast office, which will deliver all Phlexglobal’s TMF services including the PhlexEview eTMF solution, will initially employ 20 staff, growing to 50 employees within the first year of operation.
In addition to providing a base for Phlexglobal’s resource solutions and operations task force, the 800 square metre office will also house a new records centre, securely storing live TMF documents for Phlexglobal clients across the United States.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
